Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination therapy consisting of dopexamine and norepinephrine. Dopexamine is a synthetic analogue of dopamine that stimulates beta-2 adrenergic receptors and peripheral dopamine receptors (D1 and D2), while also inhibiting the neuronal re-uptake of norepinephrine. Norepinephrine is a potent alpha-adrenergic agonist with less pronounced beta-adrenergic effects. This combination is used primarily in the management of septic shock, where it has shown beneficial effects on gastric mucosal blood flow compared to epinephrine alone. The combination works by balancing the strong vasoconstrictive effects of norepinephrine with the inotropic and vasodilatory properties of dopexamine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dopexamine + norepinephrine.